Advertisement
Singapore markets close in 3 hours 7 minutes
  • Straits Times Index

    3,302.57
    +9.64 (+0.29%)
     
  • Nikkei

    38,236.07
    -38.03 (-0.10%)
     
  • Hang Seng

    18,432.17
    -43.75 (-0.24%)
     
  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     
  • Bitcoin USD

    64,201.91
    +897.38 (+1.42%)
     
  • CMC Crypto 200

    1,336.52
    +59.54 (+4.66%)
     
  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     
  • Dow

    38,675.68
    +449.98 (+1.18%)
     
  • Nasdaq

    16,156.33
    +315.33 (+1.99%)
     
  • Gold

    2,320.60
    +12.00 (+0.52%)
     
  • Crude Oil

    78.50
    +0.39 (+0.50%)
     
  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     
  • FTSE Bursa Malaysia

    1,593.98
    +4.39 (+0.28%)
     
  • Jakarta Composite Index

    7,150.90
    +16.18 (+0.23%)
     
  • PSE Index

    6,672.17
    +56.62 (+0.86%)
     

BioCryst to Report First Quarter 2024 Financial Results on May 6

BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc.

RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on Monday, May 6, 2024.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.

ADVERTISEMENT

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com